$FMC

FMC CORP

FMC is a global agricultural sciences company headquartered in Philadelphia, Pennsylvania. It operates in one business segment, developing, marketing and selling crop protection chemicals, including insecticides, herbicides and fungicides, as well as biologicals, crop nutrition and seed treatment products grouped as Plant Health. Its products protect crops from insects, weeds and diseases, and Plant Health products also support crop yields. FMC serves farmers and other agricultural customers through its own sales and marketing organizations, distributors, retailers, cooperatives and, in select countries, direct sales to large growers. It also serves non-agricultural markets with products for pest control and weed management. FMC makes money by selling its crop protection and plant health products and by licensing technologies and entering development, distribution and alliance agreements. Its product portfolio includes brands such as Rynaxypyr, Cyazypyr and Arc farm intelligence, a mobile platform for pest monitoring and management. Through FMC Ventures, it also invests in start-ups and early-stage companies developing agricultural technologies.

AlphAI earnings readThird quarter 2026 · OCT 29FMC Corporation Reports Third-Quarter 2026 Results and Revised Fourth-Quarter OutlookVerdict: weak

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
4
$14K
$32K
Tack Luc Jules R
50%
See all $FMC insider activity →
Med

Yeti downgraded, Humana upgraded: Wall Street's top analyst calls

RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.

KeyBanc downgrades FMC stock rating on turnaround concerns

KeyBanc downgraded FMC Corp. (NYSE:FMC) to Sector Weight, citing risks to its turnaround efforts. The stock, at $5.21, has fallen 61.5% in a year. KeyBanc set a fair value of $5.50, while InvestingPro's analysis suggests a Fair Value of $6.36. FMC plans to raise $1 billion, including $400 million in equity, and anticipates a return to growth in 2027. Jefferies initiated coverage with a Hold rating and a $6.00 price target.

FMC renews retreat, slumps 13%

FMC Corporation (FMC) shares fell 13% to $4.82 on Thursday. The decline follows a revenue drop, reduced EPS guidance, and negative full-year free cash flow projection. The company also faces pricing issues, inventory challenges, and macroeconomic pressures, according to the report.

FMC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning FMC (FMC CORP). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.

Recent FMC coverage spans financial news and earnings.

In the last 30 days, FMC insiders filed 2 SEC Form 4 transactions — 1 purchase ($14K) and 1 sale ($32K). The most active reporter was Tack Luc Jules R with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving FMC

AlphAI scores every news story that mentions FMC with an AI model for sentiment and relevance, and aggregates insider trades from FMC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FMC

Score

Yeti downgraded, Humana upgraded: Wall Street's top analyst calls

RBC upgraded Humana (HUM) to Outperform with a $563 target, citing earnings potential. TD upgraded SPXC to Buy with a $200 target. Phillip upgraded ABNB to Neutral with a $184 target, expecting higher revenue growth. Gordon Haskett upgraded TXRH to Buy with a $220 target. Mizuho double upgraded VIK to Outperform with a $120 target. Goldman downgraded YETI to Neutral with a $41 target. KeyBanc downgraded FMC to Sector Weight.

KeyBanc downgrades FMC stock rating on turnaround concerns

KeyBanc downgraded FMC Corp. (NYSE:FMC) to Sector Weight, citing risks to its turnaround efforts. The stock, at $5.21, has fallen 61.5% in a year. KeyBanc set a fair value of $5.50, while InvestingPro's analysis suggests a Fair Value of $6.36. FMC plans to raise $1 billion, including $400 million in equity, and anticipates a return to growth in 2027. Jefferies initiated coverage with a Hold rating and a $6.00 price target.

FMC renews retreat, slumps 13%

FMC Corporation (FMC) shares fell 13% to $4.82 on Thursday. The decline follows a revenue drop, reduced EPS guidance, and negative full-year free cash flow projection. The company also faces pricing issues, inventory challenges, and macroeconomic pressures, according to the report.

Fresenius Medical cuts top end of 2026 profit outlook

Fresenius Medical Care adjusted its 2026 operating income outlook, now expecting a flat to mid-single-digit percentage decline, down from a previous range of decline to increase. Q3 operating income fell 5% to €545 million, while revenue grew 1% to €4.94 billion. US same-market treatments declined 1.1%. The company faces regulatory and inflation challenges under new CEO Shervin J. Korangy.

Related tickers